Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Ambrx Biopharma, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +2 vs. Q2 2022
- Shares held
- 16.7M
- −461.7K (−2.7%) vs. Q2 2022
- Total value
- $18.0M
- −$27.4M (−60.3%) vs. Q2 2022
- New holders
- 4
- 3 more added
- Sold out
- 2
- 4 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AMAM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 68 | $912.7M |
| Q3 2023 | 44 | $568.3M |
| Q2 2023 | 42 | $788.8M |
| Q1 2023 | 30 | $330.7M |
| Q4 2022 | 18 | $40.7M |
| Q3 2022 | 16 | $18.0M |
| Q2 2022 | 14 | $45.4M |
| Q1 2022 | 14 | $70.6M |
| Q4 2021 | 16 | $152.0M |
| Q3 2021 | 15 | $165.3M |
| Q2 2021 | 20 | $266.2M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Ambrx Biopharma, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 101 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 42 | $0 | 0.00% | +42 | New |
| UBS Group AG | 7,967 | $9.00K | 0.00% | +7,725+3,192.1% | Added |
| Citadel Advisors LLC | 12,116 | $13.0K | 0.00% | +12,116 | New |
| Tudor Investment Corp Et Al | 16,315 | $18.0K | 0.00% | −2,748−14.4% | Reduced |
| Susquehanna International Group, LLP | 19,220 | $21.0K | 0.00% | +19,220 | New |
| Royal Bank of Canada | 42,453 | $46.0K | 0.00% | +42,453 | New |
| Renaissance Technologies LLC | 64,000 | $69.0K | 0.00% | +53,000+481.8% | Added |
| Millennium Management LLC | 113,692 | $123.0K | 0.00% | +10,916+10.6% | Added |
| Suvretta Capital Management, LLC | 1,491,832 | $1.61M | 0.07% | 00.0% | Unchanged |
| Fosun International Ltd | 1,932,591 | $2.09M | 0.38% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,027,291 | $2.19M | 0.01% | 00.0% | Unchanged |
| Artal Group S.A. | 2,152,291 | $2.32M | 0.12% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 2,336,389 | $2.52M | 0.18% | −149,997−6.0% | Reduced |
| BlackRock Inc. | 2,851,433 | $3.08M | 0.00% | −530.0% | Reduced |
| FMR LLC | 3,588,467 | $3.88M | 0.00% | −269,212−7.0% | Reduced |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −122,800−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −62,396−100.0% | Sold out |